Genetics and epigenetic issues continue to knock open doors in toxic tort litigation. An example? A recent federal MDL ruling rejected defense Daubert motions seeking to strike expert opinions that were based on the concept of a cancer arising less than 1 year. How could that happen? Think epigenetic actions that “turn on” a cell receptor and leave it generating proteins at full throttle, and putting the cell into an agitated state in which it more easily transforms into a malignant cell.
I will be covering those issues and more on a panel with Lenn Murelle, a smart scientist who runs a company known as Venebio Group. Lenn “gets” molecular science and toxic tort litigation.
2:15 p.m. – 3:15 p.m.
Molecular Epidemiology, Epigenetics, and Nutrigenomics Bioscience – Intersections with Toxic Tort Claims
• Molecular Epidemiology and Toxic Tort Intersections
• What is Happening in the Human Body with the Increases in Obesity?
• Mesothelioma – Seeing the Intersections with BAP1 Mutation and Epigenetic Factors
• Epigenetics and Multi-Generational Toxic Tort Claims
Edward L. Murrelle, MSPH, Ph.D., Co-Founder and CEO, Venebio Group, LLC, Richmond, VA
Kirk T. Hartley, LSP Group LLC
9:00 a.m. – 10:00 a.m.
The Rapid Evolution of Law With Quantitative Precision Science
Len van Zyl, Ph.D., CEO and CSO, ArrayXpress, Inc., Raleigh, NC
Michael Zapata III, Executive Chairman, ArrayXpress, Inc., Raleigh, NC
10:00 a.m. – 10:45 a.m.
Understanding The Application of Epidemiology to the Science of Genomics
David G. Hoel, Ph.D., Exponent, Inc., Alexandria, VA
11:00 a.m. – 12:00 p.m.
The Role of Medical Toxicology and Ethical Issues
D. Mark Jackson, Bassi Edlin Huie & Blum LLP, San Francisco
John B. Sullivan, M.D., MBA, University of Arizona, Department of Emergency Medicine/Medical Toxicology Division, Tucson, AZ (Retired)